Call for Abstract

2nd International Conference on Clinical Trials and Therapeutic Drug Monitoring, will be organized around the theme “Discoveries and Developments for Safer Medication”

Drug Monitoring 2016 is comprised of 16 tracks and 138 sessions designed to offer comprehensive sessions that address current issues in Drug Monitoring 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Investigational new drug process
  • Track 1-2In Vitro and In Vivo screening
  • Track 1-3Developing pharmacological profile of the drug
  • Track 1-4Conducting toxicity studies
  • Track 1-5Pre-clinical research leading to clinical trials
  • Track 2-1Conducts of pediatrics and geriatrics Clinical Trials
  • Track 2-2 Misconduct and Fraud in clinical trials
  • Track 2-3 Emerging breakthroughs
  • Track 2-4Patient recruitment
  • Track 2-5 Types of clinical trials
  • Track 2-6 Public and Patient involvement
  • Track 2-7Clinical research phase studies
  • Track 2-8Barriers and solutions to clinical trial recruitment
  • Track 2-9 Risks and benefits of participants
  • Track 2-10New drug application
  • Track 2-11 Preparing data for FDA submission
  • Track 3-1Design and end points of clinical trials
  • Track 3-2Clinical testing
  • Track 3-3Randomized placebo- controlled trials
  • Track 3-4Trial and protocol designs that reflects patient considerations
  • Track 3-5Patient consideration and patient oriented trial designs
  • Track 3-6Adaptive Clinical Trials
  • Track 3-7Randomized Clinical Trials
  • Track 3-8Experimental Study designs
  • Track 3-9Observational study designs
  • Track 3-10Trial design: formulation development, manufacturing and analytical testing
  • Track 3-11Study designs for medical devices
  • Track 4-1Innovative partnering in clinical research
  • Track 4-2Implementation of mobile health technologies
  • Track 4-3Innovations in patient and community engagement in clinical trials
  • Track 4-4Creating patient centric trials
  • Track 4-5Driving innovation in patient recruitment
  • Track 4-6Collaborate with patients to boost trial productivity
  • Track 4-7Supporting continuous quality improvement through e-Clinical technology
  • Track 4-8Innovation in clinical research technologies and software systems
  • Track 4-9Strategic development towards FDA approval
  • Track 4-10Global needs for mobile health and potential technologies
  • Track 5-1Data management plan development
  • Track 5-2Data types and data processing techniques
  • Track 5-3CRF/eCRF design and development
  • Track 5-4Electronic data capturing systems
  • Track 5-5Handling the complexities in managing non-CRF data
  • Track 5-6On-shore & off-shore clinical data management
  • Track 5-7Metrics to quantify clinical data quality
  • Track 5-8Statistical analysis methods
  • Track 5-9SAS programming in data analysis
  • Track 5-10Advanced products in data management
  • Track 5-11Data integration and visualization
  • Track 6-1Diabetes Mellitus Type 1 Clinical Trials
  • Track 6-2Diabetes Mellitus Type 2 Clinical Trials
  • Track 6-3Breast cancer research and trials
  • Track 6-4Brain, Spine, Lung, Kidney, Blood, Skin and all other cancers research and trials
  • Track 6-5Clinical research and Trials on HIV/AIDS
  • Track 7-1Research and Trials on Cardiovascular diseases and devices
  • Track 7-2Studies on parasitic, viral, bacterial and fungal diseases
  • Track 7-3Trials on digestive system and respiratory system diseases
  • Track 7-4Asthma Clinical Trials
  • Track 7-5Clinical trials on rare diseases
  • Track 7-6Research and Trials on behaviors, mental, eating and sleep disorders
  • Track 7-7Research and Studies on wounds and injuries
  • Track 7-8Trials on surgical and home use Medical Devices
  • Track 8-1Europe Clinical Trials
  • Track 8-2UK Clinical Trials
  • Track 8-3Japan Clinical Trials
  • Track 8-4USA Clinical Trials
  • Track 8-5Canada Clinical Trials
  • Track 8-6Asia Clinical Trials
  • Track 9-1Basis for a successful sponsor-CRO Partnership
  • Track 9-2Business development tactics for clinical research sites
  • Track 9-3Strategies to attract sponsors and CRO’s
  • Track 9-4Cloud based medical image management for clinical trials
  • Track 9-5Clinical development of the future
  • Track 9-6Clinical trial site of the future
  • Track 9-7Mobile technology
  • Track 10-1Compliance and regulatory requirements in clinical research
  • Track 10-2Bioethics: Case studies and Ethical regulatory guidelines
  • Track 10-3Ethical and regulatory issues
  • Track 10-4Techniques for designing case report forms in clinical research
  • Track 10-5Breast cancer case reports
  • Track 10-6Case reports in oncology, diabetes and cardiovascular diseases
  • Track 10-7Dermatology, gastroenterology, Nephrology, pulmonology and urology case reports
  • Track 10-8Case reports in neurology, ophthalmology, obstetrics and gynecology
  • Track 11-1Building an action plan in CTS
  • Track 11-2Site management in clinical research
  • Track 11-3Selection and benefits of CTMS
  • Track 11-4Fundamentals of outsourcing in clinical devices
  • Track 11-5Globalization & Outsourcing
  • Track 11-6Strategic or tactical outsourcing
  • Track 12-1New therapeutic targets in drug design/discovery
  • Track 12-2Evaluation of dose related toxicity and therapeutic inefficacy
  • Track 12-3Individual Drugs TDM
  • Track 12-4TDM Challenges and Advances
  • Track 12-5Thin layer chromatography (TLC), HPLC and GLS
  • Track 12-6Radio immuno assay (RIA) and Enzyme Immuno assay
  • Track 12-7Fluorescence polarization Immunoassay (FPIA)
  • Track 12-8Gender & Pathophysiology
  • Track 12-9OMICS Technologies
  • Track 13-1Absorption
  • Track 13-2Bioavailability
  • Track 13-3Effect of age
  • Track 13-4Biotransformation
  • Track 13-5Enzyme inhibition and induction
  • Track 13-6Lipid solubility
  • Track 13-7Interaction with foods or other drugs
  • Track 13-8Patient compliance and Protein binding
  • Track 13-9Adverse Outcome Pathways
  • Track 14-1Toxicogenomics in regulatory application
  • Track 14-2SAR/QSAR models
  • Track 14-3Screening tools to predict toxicity & targets
  • Track 14-4Signature/biomarker qualification
  • Track 14-5Bioinformatics and interpretive challenges in toxicogenomics
  • Track 14-6Challenges of conventional toxicology approaches
  • Track 14-7Toxicogenomics as a predictive tool
  • Track 14-8Environmental and Comparative Toxicogenomics
  • Track 14-9Toxicogenomics Roles
  • Track 14-10Hypothesis generation to aid in the determination of MOA(s)
  • Track 15-1Priorities and needs of PV at different stages of a product life-cycle
  • Track 15-2Challenges and opportunities in PV lifecycle management
  • Track 15-3IT solutions for pharmacovigilance
  • Track 15-4Safety surveillance and risk management lifecycle
  • Track 15-5Innovation and trends in clinical drug safety